117 related articles for article (PubMed ID: 29794161)
1. Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors.
Visentin M; Torozi A; Gai Z; Häusler S; Li C; Hiller C; Schraml PH; Moch H; Kullak-Ublick GA
Drug Metab Dispos; 2018 Aug; 46(8):1129-1136. PubMed ID: 29794161
[TBL] [Abstract][Full Text] [Related]
2. Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.
Gai Z; Visentin M; Hiller C; Krajnc E; Li T; Zhen J; Kullak-Ublick GA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5573-80. PubMed ID: 27401566
[TBL] [Abstract][Full Text] [Related]
3. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
4. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2.
Shu W; Ma L; Hu X; Zhang M; Chen W; Ma W; Huang J; Li J
Eur J Pharm Sci; 2020 Jan; 142():105153. PubMed ID: 31740393
[TBL] [Abstract][Full Text] [Related]
5. Plasma Membrane Cholesterol Regulates the Allosteric Binding of 1-Methyl-4-Phenylpyridinium to Organic Cation Transporter 2 (SLC22A2).
Hörmann S; Gai Z; Kullak-Ublick GA; Visentin M
J Pharmacol Exp Ther; 2020 Jan; 372(1):46-53. PubMed ID: 31624079
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
Arakawa H; Omote S; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
[TBL] [Abstract][Full Text] [Related]
7. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
8. Activation of liver X receptor inhibits OCT2-mediated organic cation transport in renal proximal tubular cells.
Wongwan T; Kittayaruksakul S; Asavapanumas N; Chatsudthipong V; Soodvilai S
Pflugers Arch; 2017 Nov; 469(11):1471-1481. PubMed ID: 28741179
[TBL] [Abstract][Full Text] [Related]
9. Effect of 7-ketocholesterol incorporation on substrate binding affinity and turnover rate of the organic cation transporter 2 (OCT2).
Xiu F; Console L; Indiveri C; Su S; Wang T; Visentin M
Biochem Pharmacol; 2024 Feb; 220():116017. PubMed ID: 38176620
[TBL] [Abstract][Full Text] [Related]
10. Organic cation transporter 2 (SLC22A2), a low-affinity and high-capacity choline transporter, is preferentially enriched on synaptic vesicles in cholinergic neurons.
Nakata T; Matsui T; Kobayashi K; Kobayashi Y; Anzai N
Neuroscience; 2013 Nov; 252():212-21. PubMed ID: 23958595
[TBL] [Abstract][Full Text] [Related]
11. Key role of organic cation transporter 2 for the nephrotoxicity effect of triptolide in rheumatoid arthritis.
Shen Q; Wang J; Yuan Z; Jiang Z; Shu T; Xu D; He J; Zhang L; Huang X
Int Immunopharmacol; 2019 Dec; 77():105959. PubMed ID: 31644961
[TBL] [Abstract][Full Text] [Related]
12. Incorporating renal excretion via the OCT2 transporter in physiologically based kinetic modelling to predict in vivo kinetics of mepiquat in rat.
Noorlander A; Wesseling S; Rietjens IMCM; van Ravenzwaay B
Toxicol Lett; 2021 Jun; 343():34-43. PubMed ID: 33639197
[TBL] [Abstract][Full Text] [Related]
13. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
PLoS One; 2017; 12(12):e0189521. PubMed ID: 29236753
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.
Zolk O; Solbach TF; König J; Fromm MF
Drug Metab Dispos; 2009 Jun; 37(6):1312-8. PubMed ID: 19251820
[TBL] [Abstract][Full Text] [Related]
15. Regulation of
Zhu Q; Yu L; Qin Z; Chen L; Hu H; Zheng X; Zeng S
Epigenetics; 2019 Aug; 14(8):791-803. PubMed ID: 31088315
[TBL] [Abstract][Full Text] [Related]
16. Substrate-Dependent
Lefèvre CR; Le Vée M; Gaubert S; Jouan E; Bruyere A; Moreau C; Fardel O
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884730
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.
Liu Y; Zheng X; Yu Q; Wang H; Tan F; Zhu Q; Yuan L; Jiang H; Yu L; Zeng S
Sci Transl Med; 2016 Jul; 8(348):348ra97. PubMed ID: 27440728
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Organic Cation Transporter 2 and a Na
Sarkar S; Berry MD
Life Sci; 2020 Jul; 253():117696. PubMed ID: 32334013
[TBL] [Abstract][Full Text] [Related]
19. The role of cholesterol recognition (CARC/CRAC) mirror codes in the allosterism of the human organic cation transporter 2 (OCT2, SLC22A2).
Sutter ML; Console L; Fahner AF; Samodelov SL; Gai Z; Ciarimboli G; Indiveri C; Kullak-Ublick GA; Visentin M
Biochem Pharmacol; 2021 Dec; 194():114840. PubMed ID: 34774844
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).
Zolk O; Solbach TF; König J; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2009 Apr; 379(4):337-48. PubMed ID: 19002438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
